-
Functional Areas
- Audit and Investigations
-
Capacity development and transition, strengthening systems for health
- A Strategic Approach to Capacity Development
- Capacity Development and Transition - Lessons Learned
- Capacity development and Transition Planning Process
- Capacity Development and Transition
- Capacity Development Objectives and Transition Milestones
- Capacity Development Results - Evidence From Country Experiences
- Functional Capacities
- Interim Principal Recipient of Global Fund Grants
- Legal and Policy Enabling Environment
- Overview
- Resilience and Sustainability
- Transition
-
Financial Management
- CCM Funding
- Grant Closure
- Grant Implementation
- Grant-Making and Signing
- Grant Reporting
- Overview
- Sub-recipient Management
-
Grant closure
- Overview
-
Steps of Grant Closure Process
- 1. Global Fund Notification Letter 'Guidance on Grant Closure'
- 2. Preparation and Submission of Grant Close-Out Plan and Budget
- 3. Global Fund Approval of Grant Close-Out Plan
- 4. Implementation of Close-Out Plan and Completion of Final Global Fund Requirements (Grant Closure Period)
- 5. Operational Closure of Project
- 6. Financial Closure of Project
- 7. Documentation of Grant Closure with Global Fund Grant Closure Letter
- Terminology and Scenarios for Grant Closure Process
- Human resources
- Human rights, key populations and gender
-
Legal Framework
- Agreements with Sub-sub-recipients
- Amending Legal Agreements
- Implementation Letters and Management Letters
- Language of the Grant Agreement and other Legal Instruments
- Legal Framework for Other UNDP Support Roles
- Other Legal and Implementation Considerations
- Overview
- Project Document
- Signing Legal Agreements and Requests for Disbursement
-
The Grant Agreement
- Grant Confirmation: Conditions Precedent (CP)
- Grant Confirmation: Conditions
- Grant Confirmation: Face Sheet
- Grant Confirmation: Limited Liability Clause
- Grant Confirmation: Schedule 1, Integrated Grant Description
- Grant Confirmation: Schedule 1, Performance Framework
- Grant Confirmation: Schedule 1, Summary Budget
- Grant Confirmation: Special Conditions (SCs)
- Grant Confirmation
- UNDP-Global Fund Grant Regulations
- Monitoring and Evaluation
- Principal Recipient Start-Up
-
Procurement and Supply Management
- Development of List of Health Products and Procurement Action Plan
- Distribution and Inventory Management
- Overview
- Price and Quality Reporting (PQR) System
- Procurement of Non-health Products and Services
- Procurement of Pharmaceutical and Other Health Products
- Quality Control
- Rational use of Medicines and Pharmacovigilance Systems
- Strengthening of PSM Services and Risk Mitigation
- UNDP Health PSM Roster
- UNDP Quality Assurance Policy and Plan
-
Reporting
- Communicating Results
- Grant Performance Report
- Overview
- Performance-based Funding and Disbursement Decision
- PR and Coordinating Mechanism (CM) Communication and Governance
- Reporting to the Global Fund
- UNDP Corporate Reporting
-
Risk Management
- Common Risks Identified in Global Fund Programmes
- Global Fund Risk Management
- Introduction to Risk Management
- Overview
- Risk Management in High Risk Environments
- Risk Management in UNDP-managed Global Fund Grants
- Risk management in UNDP
- UNDP Risk Management in the Global Fund Portfolio
- Sub-Recipient Management
Distribution and Inventory Management
Some of the key elements necessary to ensure that medical products actually reach the intended users are adequate storage and distribution systems. Existing public health storage facilities and distribution are the logistics channels of choice, if they are adequate or if deficiencies can be remedied during the programme. If not, then storage facilities run by non-governmental organizations (NGOs) and international organizations may be a viable alternative. It may also be possible to use private facilities and distribution networks run by commercial companies while public health facilities are improved.
Before medical products are procured, the Principal Recipient (PR) must verify the following:
- the storage space for the products is adequate with respect to volume as well as quality (clean, dry, not subject to excessive heat or light, temperature-controlled areas available, if needed, all storage areas free of rodents) and the facilities are secure, with storage areas assessed using the WHO Guidelines for the Storage of Essential Medicines and Other Health Commodities;
-
there are inventory and information collection systems at each distribution and treatment site sufficient to monitor consumption rates and prevent diversion, stock-outs or expiration of products;
- the inventory and information collection systems are sufficient; if not, it may be necessary to use grant funds to procure/develop a computerized inventory and information collection system;
- distribution and inventory management systems include a mechanism to trace, by batch number, the patients to whom antiretrovirals (ARVs) and other sensitive drugs are distributed, in the event that the product is recalled; and
- all storage facilities and personnel use the ‘first expired, first out’ (FEFO) system.
The distribution network should be evaluated to ensure that there will be a constant supply of medicines. First, it is necessary to confirm the location and adequacy of the different distribution points needed, such as central medical stores, regional stores, local treatment sites etc. It is then necessary to identify any significant distribution challenges, such as the following:
- lack of adequate roads;
- seasonal problems such as flooding;
- areas of internal conflict;
- insufficient transport capacity; and
- long distances between distribution points.
The existence of one or more of these significant challenges will affect the next decision about the distribution network—namely, which method of transportation will be used. It may be a good idea to do a test run of the distribution route to estimate the delivery times and make sure that the route is adequate before starting out in a vehicle full of fragile products.
Once the products arrive, it is important to use the inventory and information collection system to monitor forecasts against actual consumption rates. Only by monitoring this information can stock-outs be avoided and a continuous supply of medicines guaranteed.
It is also important for the programme to do periodic audits and inspections of all points in the distribution chain. This will confirm that information is being accurately reported and to help prevent diversion of valuable commodities.
Loading resources
